Dabrafenib and/or Trametinib Rollover Study | MicrobiomeTrials← Back to trialsNCT03340506
Dabrafenib and/or Trametinib Rollover Study
RecruitingPHASE4INTERVENTIONAL
Trial Details
Start: 2017-12-28Est. Completion: 2032-12-28
Enrollment target: 100 participants Locations- Honor Health Research Institute, Scottsdale, Arizona, United States
- Honor Health Research Institute, Scottsdale, Arizona, United States
- National Institute Of Health, Bethesda, Maryland, United States
- James Cancer Hospital and Solove Research Institute Ohio State, Columbus, Ohio, United States
- Mary Crowley Cancer Research, Dallas, Texas, United States
- Novartis Investigative Site, Caba, Buenos Aires, Argentina
- Novartis Investigative Site, Innsbruck, Tyrol, Austria
- Novartis Investigative Site, Beijing, China
- Novartis Investigative Site, Copenhagen, Denmark
- Novartis Investigative Site, Lyon, France
- Novartis Investigative Site, Nantes, France
- Novartis Investigative Site, Paris, France
- Novartis Investigative Site, Villejuif, France
- Novartis Investigative Site, Mannheim, Baden-Wurttemberg, Germany
- Novartis Investigative Site, Berlin, Germany
- Novartis Investigative Site, Hamburg, Germany
- Novartis Investigative Site, Heidelberg, Germany
Other microbiome trials you might be interested in
MelanomaLi-Fraumeni SyndromePulmonary BlastomaChordomaCongenital Bone Marrow Failure SyndromesCostello SyndromeFanconi AnemiaCFC Syndrome (CFCS)Legius SyndromeRASopathies
Background:
Clinical Genetics Branch (CGB) researchers study individuals and populations at high genetic risk of cancer…
Rockville, United StatesEst. completion Jan 1, 2035
Recurrent Melanoma (Skin)
Novartis Investigative Site, Debrecen, Hajdu Bihar Megye, HungaryNovartis Investigative Site, Budapest, HungaryNovartis Investigative Site, Kashiwa, Chiba, JapanNovartis Investigative Site, Chuo Ku, Tokyo, JapanNovartis Investigative Site, Rotterdam, South Holland, NetherlandsNovartis Investigative Site, Utrecht, NetherlandsNovartis Investigative Site, Barcelona, SpainNovartis Investigative Site, Madrid, SpainNovartis Investigative Site, Madrid, SpainNovartis Investigative Site, Madrid, SpainNovartis Investigative Site, Madrid, SpainNovartis Investigative Site, Songkhla, Hat Yai, ThailandMetastatic Melanoma
Melanoma Stage IV
Melanoma Stage III
In this first-in human, phase I/IIa study, the safety and efficacy of \[212Pb\]VMT01, an alpha-particle emitting therape…
Orange, United StatesEst. completion Dec 31, 2027